News and Events
Get the latest news and event updates from Nuvaira.
News and Events
Jan 25, 2022
200th Treatment Milestone for AIRFLOW-3 COPD Trial
300 Patients Treated Worldwide with dNerva® Targeted Lung Denervation therapy MINNEAPOLIS, January 25, 2022 – Nuvaira, a developer of novel therapeutic strategies…
Jun 08, 2020
Nuvaira Announces FDA Breakthrough Designation for AIRFLOW-3 Pivotal Trial Device
Inspire Medical Systems CEO Tim Herbert has joined Nuvaira Board of Directors MINNEAPOLIS, June 8, 2020 – Nuvaira, a developer of novel therapeutic strategies…
Feb 04, 2020
Nuvaira Announces Chief Financial Officer and Pivotal Study Milestone
Seasoned Veteran Tom Griffin Joins Nuvaira’s Executive Team MINNEAPOLIS, Feb. 4, 2020 – Nuvaira, a developer of novel therapeutic strategies to treat obstructive…
Aug 19, 2019
Nuvaira Announces Peer-Reviewed Publications of Targeted Lung Denervation Mechanisms of Action and Clinical Outcomes
AIRFLOW-2 randomized, sham-controlled one-year data accepted by AJRCCM MINNEAPOLIS, Aug 19, 2019 – Nuvaira, a developer of novel therapeutic strategies to…
Feb 11, 2019
Nuvaira Announces a $79 Million Financing Round to Pursue Groundbreaking Treatment of COPD
Market Development Veteran Lisa Rogan Joins Nuvaira’s Executive Team MINNEAPOLIS, Feb 11, 2019 – Nuvaira, a developer of novel therapeutic medical devices…